BridgeBio Pharma, Inc. — Q1 2022 Form 10-Q Summary
Business context and reporting period
BridgeBio is a commercial-stage biopharmaceutical company developing medicines for genetically driven diseases and cancers through wholly owned and controlled subsidiaries. The filing covers the unaudited three months ended March 31, 2022, compared with the three months ended March 31, 2021. The company reported more than 15 ongoing clinical trials, two FDA-approved products, and a pipeline spanning early research through advanced clinical development.
Financial performance and liquidity
| Metric | Q1 2022 | Q1 2021 | Change |
|---|---|---|---|
| Total revenue | $1.7 million | $0.5 million | +$1.2 million |
| License revenue | $0.2 million | $0.5 million | -$0.2 million |
| Product sales | $1.5 million | — | +$1.5 million |
| Cost of license revenue and products sold | $1.3 million | — | +$1.3 million |
| Research and development | $107.6 million | $122.6 million | -$14.9 million |
| Selling, general and administrative | $43.7 million | $45.4 million | -$1.7 million |
| Restructuring, impairment and related charges | $22.7 million | — | +$22.7 million |
| Loss from operations | $(173.7) million | $(167.5) million | $(6.2) million |
| Net loss | $(201.3) million | $(171.1) million | $(30.2) million |
| Net loss attributable to BridgeBio common stockholders | $(196.4) million | $(163.1) million | $(33.3) million |
| Loss per share | $(1.35) | $(1.18) | — |
Revenue less product and license costs produced approximately $0.3 million of gross profit, but revenue remained immaterial relative to operating expenses. Net cash used in operating activities was $160.6 million, compared with $150.8 million in the prior-year quarter. Investing activities provided $138.6 million, primarily from maturities of marketable securities and proceeds from asset sales. Financing activities used approximately $0.2 million.
At March 31, 2022, cash and cash equivalents were $371.6 million, marketable securities were $261.9 million, and investment in equity securities was $37.8 million. Cash, cash equivalents and marketable securities totaled $633.5 million, down from $787.5 million at December 31, 2021. Management stated that available liquidity, including equity securities, is expected to fund operations for at least the next 12 months under current plans.
Debt consisted principally of $747.5 million principal of 2.25% convertible notes due 2029, $550.0 million principal of 2.50% convertible notes due 2027, and a $450.0 million funded term loan bearing 9.0% interest, of which 3.0% may be paid in kind. Net carrying amounts were $733.6 million, $540.4 million and $434.1 million, respectively. Total debt net of discounts and issuance costs was approximately $1.7 billion. Interest expense increased to $20.3 million from $9.7 million.
Material changes versus the prior comparable period
- Research and development expense declined 12%, primarily because of lower stock-based compensation and program reprioritization.
- Net loss increased 18%, driven by higher interest expense, investment losses, restructuring charges and other unusual items.
- The company recorded $12.9 million of realized and unrealized losses on equity securities, principally reflecting mark-to-market losses.
- The company recognized a $12.5 million gain for a receivable from Helsinn related to reimbursement of an obligation to Foundation Medicine.
- Origin completed the sale of NULIBRY and related assets to Sentynl for $10.0 million upfront and recognized a $6.3 million loss on sale.
- BridgeBio recorded $22.7 million of restructuring, impairment and related charges, including $12.7 million of long-lived-asset impairments and write-offs, $7.0 million of severance and employee-related costs, and $3.0 million of exit-related costs.
- QED amended its Helsinn agreement effective March 1, 2022. Helsinn became responsible for specified development, manufacturing and commercialization activities outside Greater China, while QED retained skeletal dysplasia rights. QED no longer expects to recognize product sales for the remainder of 2022.
- Helsinn reimbursements reduced research and development expense by $6.2 million and selling, general and administrative expense by $1.2 million in the quarter.
Guidance, outlook, risks and unusual items
- Management expects continued operating and net losses for at least the next several years and does not expect product sales for the remainder of 2022 because commercialization activities have transferred or transitioned to partners.
- Full-year 2022 restructuring charges are estimated at approximately $23 million to $25 million; actual amounts depend in part on the ability to sublease office space.
- The company expects meaningful operating-cost savings from the restructuring initiative.
- COVID-19 may delay patient enrollment, clinical trials, nonclinical experiments, manufacturing and other development activities. Inflationary pressures and broader economic conditions may also affect results.
- Liquidity depends on continued access to capital, potential partnerships and licensing transactions, asset monetizations, and the successful development and commercialization of product candidates. Additional financing may be required sooner if operating plans or forecasts change.
- The term loan is secured by substantially all assets of BridgeBio and certain guarantors and includes covenants, mandatory prepayment provisions tied to certain monetization or disposition transactions, and events of default that could permit acceleration.
- Potential performance-based milestone compensation totaled $254.5 million, of which $15.7 million was accrued as probable at March 31, 2022. License and development agreements also contain contingent milestone and royalty obligations.
- No material legal proceedings, defaults upon senior securities, or material changes to previously disclosed risk factors were reported. Disclosure controls were assessed as effective.
Important facts for investors to verify
- Whether the reported liquidity remains sufficient as operating cash burn continues at approximately $160 million per quarter and debt service increases.
- Progress, clinical results and regulatory timing for acoramidis, infigratinib, encaleret, BBP-631, BBP-454 and other priority programs.
- The timing and financial impact of the Helsinn transition, including royalties, reimbursements, milestone eligibility and the absence of expected 2022 product sales.
- Final costs and savings from the restructuring initiative, including facility exits, subleasing assumptions and workforce reductions.
- Potential dilution from the convertible notes, stock awards and performance-based milestone arrangements; approximately 65.8 million potentially dilutive common-stock equivalents were excluded from Q1 2022 diluted loss per share.
- Debt maturities, the 9.0% secured term loan, mandatory prepayment provisions and the availability of the additional $300.0 million term-loan tranche, which is subject to clinical milestones and available through December 31, 2022.